Monoclonal antibodies in treatment of myasthenia gravis
10.3760/cma.j.issn.1671-8925.2018.08.019
- VernacularTitle:单克隆抗体在重症肌无力治疗中的应用进展
- Author:
Xiaojun CAI
1
,
2
;
Wenhua ZHU
;
Jue LIU
;
Hao WEN
;
Zaiwang LI
;
Zheng JIAO
Author Information
1. 214023 无锡,南京医科大学附属无锡市人民医院药学部
2. 复旦大学附属华山医院
- Keywords:
Myasthenia gravis;
Autoimmunity;
Monoclonal antibody;
Immunotherapy
- From:
Chinese Journal of Neuromedicine
2018;17(8):851-855
- CountryChina
- Language:Chinese
-
Abstract:
Myasthenia gravis (MG) is an anti-acetylcholine receptor antibody mainly mediated,T cellular dependent and multiple complement involved acquired autoimmune disease.Anticholinesterase drug (pyridostigmine bromide),corticosteroid and azathioprine are usually used as first-line therapy due to their demonstrated effect in patients with diagnosed MG.Nevertheless,some patients with refractory MG cannot benefit from conventional treatment,and long-term application of agents may lead to obvious side effects.Recently,the emerging monoclonal antibodies with higher safety and specific targets may provide new treatment options for MG.This review discussed the currently latest research progress in this field.
